Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism is Associated with the Severity of Nonalcoholic Fatty Liver Disease

Overview

Journal Cell Metab

Publisher Cell Press

Specialties Cell Biology
Endocrinology

Date 2012 May 8

PMID 22560219

Citations 285

Authors

Hae-Ki Min

Ashwani Kapoor

Michael Fuchs

Faridoddin Mirshahi

Huiping Zhou

James Maher

John Kellum

Russell Warnick

Melissa J Contos

Arun J Sanyal

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular and liver-related mortality. NAFLD is characterized by both triglyceride and free cholesterol (FC) accumulation without a corresponding increment in cholesterol esters. The aim of this study was to evaluate the expression of cholesterol metabolic genes in NAFLD and relate these to disease phenotype. NAFLD was associated with increased SREBP-2 maturation, HMG CoA reductase (HMGCR) expression and decreased phosphorylation of HMGCR. Cholesterol synthesis was increased as measured by the circulating desmosterol:cholesterol ratio. miR-34a, a microRNA increased in NAFLD, inhibited sirtuin-1 with downstream dephosphorylation of AMP kinase and HMGCR. Cholesterol ester hydrolase was increased while ACAT-2 remained unchanged. LDL receptor expression was significantly decreased and similar in NAFLD subjects on or off statins. HMGCR expression was correlated with FC, histologic severity of NAFLD and LDL-cholesterol. These data demonstrate dysregulated cholesterol metabolism in NAFLD which may contribute to disease severity and cardiovascular risks.

Citing Articles

Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).

PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.

Early-life antibiotic exposure aggravates hepatic steatosis through enhanced endotoxemia and lipotoxic effects driven by gut .

Zhang X, Chan D, Zhu J, Sin D, Peng Y, Wong M MedComm (2020). 2025; 6(3):e70104.

PMID: 39968496 PMC: 11832435. DOI: 10.1002/mco2.70104.

Myricitrin Alleviates Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease in High Cholesterol Diet-Fed Mice.

Kim Y, Park S, Kim H, Kim S, Jung U Nutrients. 2025; 17(3).

PMID: 39940273 PMC: 11820093. DOI: 10.3390/nu17030415.

Role of the FOXM1/CMA/ER stress axis in regulating the progression of nonalcoholic steatohepatitis.

Ma S, Xia E, Zhang M, Hu Y, Tian S, Zheng X Clin Transl Med. 2025; 15(2):e70202.

PMID: 39924645 PMC: 11807764. DOI: 10.1002/ctm2.70202.

Comprehensive profiling of serum microRNAs in normal and non-alcoholic fatty liver disease (NAFLD) patients.

Zhang J, Ullah K, Khan N, Pan H Sci Rep. 2025; 15(1):3766.

PMID: 39885249 PMC: 11782575. DOI: 10.1038/s41598-025-87791-1.

References

Puri P, Mirshahi F, Cheung O, Natarajan R, Maher J, Kellum J . Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2007; 134(2):568-76. DOI: 10.1053/j.gastro.2007.10.039. View

Chaudhary N, Pfluger P . Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care. 2009; 12(4):431-7. DOI: 10.1097/MCO.0b013e32832cdaae. View

Hanley A, Williams K, Festa A, Wagenknecht L, DAgostino Jr R, Haffner S . Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54(11):3140-7. DOI: 10.2337/diabetes.54.11.3140. View

Wang Z, Yao T, Song Z . Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res. 2009; 34(3):471-8. PMC: 3260025. DOI: 10.1111/j.1530-0277.2009.01111.x. View

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

Brea A, Mosquera D, Martin E, Arizti A, Cordero J, Ros E . Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005; 25(5):1045-50. DOI: 10.1161/01.ATV.0000160613.57985.18. View

Browning J, Horton J . Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114(2):147-52. PMC: 449757. DOI: 10.1172/JCI22422. View

Matthan N, Resteghini N, Robertson M, Ford I, Shepherd J, Packard C . Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res. 2009; 51(1):202-9. PMC: 2789780. DOI: 10.1194/jlr.M900032-JLR200. View

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L . Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30(5):1212-8. DOI: 10.2337/dc06-2247. View

10.

Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

11.

Burg J, Espenshade P . Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res. 2011; 50(4):403-10. PMC: 3184313. DOI: 10.1016/j.plipres.2011.07.002. View

12.

Ikonen E . Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008; 9(2):125-38. DOI: 10.1038/nrm2336. View

13.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

14.

Geng Y, Phillips J, Mason R, Casscells S . Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochem Pharmacol. 2003; 66(8):1485-92. DOI: 10.1016/s0006-2952(03)00502-1. View

15.

Puri P, Baillie R, Wiest M, Mirshahi F, Choudhury J, Cheung O . A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007; 46(4):1081-90. DOI: 10.1002/hep.21763. View

16.

Goldstein J, Brown M . The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29(4):431-8. PMC: 2740366. DOI: 10.1161/ATVBAHA.108.179564. View

17.

Horton J, Cohen J, Hobbs H . Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007; 32(2):71-7. PMC: 2711871. DOI: 10.1016/j.tibs.2006.12.008. View

18.

Beg Z, Stonik J, BREWER Jr H . Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase. J Biol Chem. 1985; 260(3):1682-7. View

19.

Caballero F, Fernandez A, de Lacy A, Fernandez-Checa J, Caballeria J, Garcia-Ruiz C . Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009; 50(4):789-96. DOI: 10.1016/j.jhep.2008.12.016. View

20.

Yamaguchi K, Yang L, McCall S, Huang J, Yu X, Pandey S . Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology. 2007; 47(2):625-35. DOI: 10.1002/hep.21988. View